Age-related macular degeneration: economic burden and value-based medicine analysis.
about
Alternative complement pathway deficiency ameliorates chronic smoke-induced functional and morphological ocular injuryHealth State Utility Values for Age-Related Macular Degeneration: Review and Advice.Objective functional assessment of age-related maculopathy: a special application for the multifocal electroretinogram.Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration.Chronic cigarette smoke causes oxidative damage and apoptosis to retinal pigmented epithelial cells in mice.Smoke exposure causes endoplasmic reticulum stress and lipid accumulation in retinal pigment epithelium through oxidative stress and complement activation.The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization.Psychosocial adaptations to dual sensory loss in middle and late adulthood.The strong financial case for regenerative medicine and the regen industry.Systemic human CR2-targeted complement alternative pathway inhibitor ameliorates mouse laser-induced choroidal neovascularization.Lipids, lipoproteins, and age-related macular degenerationOutcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12.Long-term (60-month) results for the implantable miniature telescope: efficacy and safety outcomes stratified by age in patients with end-stage age-related macular degeneration.Factors affecting visual acuity after one year of follow up after repeated intravitreal ranibizumab for macular degenerationThe ubiquitin-proteasome system meets angiogenesis.Automated discovery and quantification of image-based complex phenotypes: a twin study of drusen phenotypes in age-related macular degeneration.The Effects of Low-Vision Rehabilitation on Reading Speed and Depression in Age Related Macular Degeneration: A Meta-AnalysisHow does the macula protect itself from oxidative stress?Long-Term Visual Outcome in Wet Age-Related Macular Degeneration Patients Depending on the Number of Ranibizumab InjectionsTargeting the tight junction protein, zonula occludens-1, with the connexin43 mimetic peptide, αCT1, reduces VEGF-dependent RPE pathophysiology.The effect of normal aging and age-related macular degeneration on perceptual learning.Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes.Surgical treatment of age-related macular degeneration: will there be a role in the future?A Targeted Inhibitor of the Alternative Complement Pathway Accelerates Recovery From Smoke-Induced Ocular InjuryAge-related maculopathy in the light of ischaemia.Different Strategies for the Treatment of Age-Related Macular Degeneration in China: An Economic EvaluationProgress in defining the molecular biology of age related macular degeneration.Naturally occurring animal models with outer retina phenotypes.Current treatment limitations in age-related macular degeneration and future approaches based on cell therapy and tissue engineering.Matrix metalloproteinase activity creates pro-angiogenic environment in primary human retinal pigment epithelial cells exposed to complement.Burden of Wet Age-Related Macular Degeneration and Its Economic Implications in Singapore in the Year 2030.Lipids, oxidized lipids, oxidation-specific epitopes, and Age-related Macular Degeneration.The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD.Joint assessment of intended and unintended effects of medications: an example using vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration.Combined treatment of exudative age related macular degeneration with photodynamic therapy and intravitreal triamcinoloneA prospective, observational, open-label, multicentre study to investigate the daily treatment practice of ranibizumab in patients with neovascular age-related macular degeneration.Three-year results of visual outcome with disease activity-guided ranibizumab algorithm for the treatment of exudative age-related macular degeneration.The national and subnational prevalence and burden of age–related macular degeneration in China.Automated Segmentation and Quantification of Drusen in Fundus and Optical Coherence Tomography Images for Detection of ARMD.Rasch analysis in the development of a simplified version of the National Eye Institute Visual-Function Questionnaire-25 for utility estimation.
P2860
Q27311630-FE87D499-3182-43EF-A67C-C5A507E49063Q30393038-8204D9EB-491A-4D14-AA9F-46418D42546CQ33226170-1F8C137A-FFF4-4B8C-B4F7-32C361DFA7A5Q33353392-1CC59E40-749E-41A6-AF6E-F186AF378E12Q33366509-8AA93B32-0241-4E50-BEB8-C220E8BFBD12Q33652041-5C7BBA55-41AB-4255-B724-30B4A6412E49Q33800561-290F3809-91B3-449E-9729-4D2999374C15Q33952336-56321E77-A0A7-4F9D-9A77-B00C9EA5C971Q34011549-CA50FCD0-6728-4E1D-BF90-4984064505ABQ34151843-9A36E02E-1457-4B7D-B5AD-1982B2829806Q35138088-1278A75E-2DB3-469D-A49A-627E83100E98Q35603537-10D4F597-8C93-4516-B0AD-C1A9DEDD2F3CQ35766506-ABC237C1-E827-4EE6-91B5-08AC04F618A7Q35806568-CC2252DF-FD32-4883-AFA6-ABC6846B8DBAQ35815625-CA1E9C09-3D30-436D-9376-AA130E68F6FEQ35826745-0A1FBF3C-52C8-4138-AA96-FC1A25B99FB2Q36077068-555D748A-C3C1-4AD6-9FFD-A7D09DE0CF31Q36083959-3B01BE68-EAC2-483E-8B93-A843E4E0B605Q36145235-63FCDA58-BA27-4255-9335-6334421D5C78Q36263301-DD25001F-2FEC-446E-84A6-CD4012F6A2D1Q36345513-5E12EE35-65F6-45AB-A676-2D0E0125AD26Q36468197-845B1486-45FF-46BA-A78E-1E4757C9FF62Q36760432-47F267FA-07B2-4D9A-87E6-1C96AFAD7F83Q36791083-D9E29FA1-A3E6-444E-BFA0-655AAF6B3F8BQ36834429-E6612D3B-3D2F-4836-A136-B390F9B6CB9EQ36864176-C0674A77-0B47-424A-B3A3-2E5A3EE10795Q36894556-10ACCC26-C108-4CA5-827F-107C1E0EA5F0Q37449638-9C56AA56-4156-456B-A05C-AB045F830BB5Q37616149-E943351D-B84E-4E1E-90ED-B5BF78C654F5Q37716557-FB1C09D8-C46E-4A4A-92DD-3105AEB2BEE9Q38848894-ED602B9D-1199-44D7-8334-1AA520FC1156Q38915148-DF098EE3-072E-4422-AB42-C7E057F58585Q39197341-17A11BCA-49D6-4F1B-92D8-83DF47810A6CQ39566377-151EA52D-C963-4C9B-B13F-953F03D35311Q41350550-8DD1ADE1-8ACA-485E-B209-6C732A1D22A5Q41713732-EE3297ED-0985-48EE-9069-6A2C03A6AA0FQ45156113-389769A0-3C4B-40F5-B5E1-5458D0AB1E72Q47102759-729271B4-56F8-4B5F-8692-BCE741E1DBD0Q47284639-A7604502-4787-4336-9620-DE81F1D33D23Q48617600-102E5243-7890-4533-891A-00F4657D442A
P2860
Age-related macular degeneration: economic burden and value-based medicine analysis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Age-related macular degeneration: economic burden and value-based medicine analysis.
@ast
Age-related macular degeneration: economic burden and value-based medicine analysis.
@en
type
label
Age-related macular degeneration: economic burden and value-based medicine analysis.
@ast
Age-related macular degeneration: economic burden and value-based medicine analysis.
@en
prefLabel
Age-related macular degeneration: economic burden and value-based medicine analysis.
@ast
Age-related macular degeneration: economic burden and value-based medicine analysis.
@en
P2093
P1476
Age-related macular degeneration: economic burden and value-based medicine analysis
@en
P2093
Gary C Brown
George R Beauchamp
Joseph Campanella
Melissa M Brown
Zachary Roth
P304
P356
10.1016/S0008-4182(05)80070-5
P50
P577
2005-06-01T00:00:00Z